S&P 500   4,305.20
DOW   34,152.01
QQQ   332.28
Companies facing 1st tax on stock buybacks in Biden bill
Investor Alert: Argentina Loaded With "White Gold" Opportunity (Ad)
Home Depot Results Point To Sluggish 2nd Half
2 Long-Term EV Plays Trading Under $20
Are These 3 Video Game Stocks Now In Play?
Investor Alert: Argentina Loaded With "White Gold" Opportunity (Ad)
What's in big Biden bill? Health, climate goals become law
Biden to sign massive climate and health care legislation
Why Apple is Primed to Take a Bite Out of Live Sports
Investor Alert: Argentina Loaded With "White Gold" Opportunity (Ad)
S&P 500   4,305.20
DOW   34,152.01
QQQ   332.28
Companies facing 1st tax on stock buybacks in Biden bill
Investor Alert: Argentina Loaded With "White Gold" Opportunity (Ad)
Home Depot Results Point To Sluggish 2nd Half
2 Long-Term EV Plays Trading Under $20
Are These 3 Video Game Stocks Now In Play?
Investor Alert: Argentina Loaded With "White Gold" Opportunity (Ad)
What's in big Biden bill? Health, climate goals become law
Biden to sign massive climate and health care legislation
Why Apple is Primed to Take a Bite Out of Live Sports
Investor Alert: Argentina Loaded With "White Gold" Opportunity (Ad)
S&P 500   4,305.20
DOW   34,152.01
QQQ   332.28
Companies facing 1st tax on stock buybacks in Biden bill
Investor Alert: Argentina Loaded With "White Gold" Opportunity (Ad)
Home Depot Results Point To Sluggish 2nd Half
2 Long-Term EV Plays Trading Under $20
Are These 3 Video Game Stocks Now In Play?
Investor Alert: Argentina Loaded With "White Gold" Opportunity (Ad)
What's in big Biden bill? Health, climate goals become law
Biden to sign massive climate and health care legislation
Why Apple is Primed to Take a Bite Out of Live Sports
Investor Alert: Argentina Loaded With "White Gold" Opportunity (Ad)
S&P 500   4,305.20
DOW   34,152.01
QQQ   332.28
Companies facing 1st tax on stock buybacks in Biden bill
Investor Alert: Argentina Loaded With "White Gold" Opportunity (Ad)
Home Depot Results Point To Sluggish 2nd Half
2 Long-Term EV Plays Trading Under $20
Are These 3 Video Game Stocks Now In Play?
Investor Alert: Argentina Loaded With "White Gold" Opportunity (Ad)
What's in big Biden bill? Health, climate goals become law
Biden to sign massive climate and health care legislation
Why Apple is Primed to Take a Bite Out of Live Sports
Investor Alert: Argentina Loaded With "White Gold" Opportunity (Ad)
OTCMKTS:EVTCY

Evotec - EVTCY Stock Forecast, Price & News

$13.80
-0.17 (-1.22%)
(As of 08/15/2022 12:00 AM ET)
Add
Compare
Today's Range
$13.78
$14.01
50-Day Range
$11.68
$14.91
52-Week Range
$14.22
$26.57
Volume
30,430 shs
Average Volume
2,407 shs
Market Capitalization
$4.56 billion
P/E Ratio
33.66
Dividend Yield
N/A
Price Target
N/A
EVTCY stock logo

About Evotec (OTCMKTS:EVTCY) Stock

Evotec SE engages in the discovery and development of new drugs for pharmaceutical and biotechnology companies. It operates through the following segments: EVT Execute and EVT Innovate. The EVT Execute segment provides stand-alone or integrated drug discovery solutions for collaborators targets and programmers on a typical fee-for-service basis or through a variety of commercial structures, which may include performance-based components, such as milestones and royalties. The EVT Innovate develops drug discovery projects, assets and platforms, both internally or through academic collaborations. The company was founded by Manfred Eigen, Karsten Henco, Ulrich Aldag, Freimut Leidenberger, Heinrich Maria Schulte, Rudolf Rigler, and Charles Weissmann on December 8, 1993 and is headquartered in Hamburg, Germany.

Receive EVTCY Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Evotec and its competitors with MarketBeat's FREE daily newsletter.

EVTCY Stock News Headlines

Evotec Q1 Adj. EBITDA Down, Revenues Up
Evotec SE reports FY results
Evotec Confirms Goals Of Action Plan 2025
Evotec SE : Evotec provides preliminary nine month financial results
See More Headlines
Receive EVTCY Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Evotec and its competitors with MarketBeat's FREE daily newsletter.

EVTCY Company Calendar

Today
8/17/2022
Fiscal Year End
12/31/2022

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
OTCMKTS:EVTCY
Employees
3,572
Year Founded
N/A

Profitability

Net Income
$7.14 million
Pretax Margin
23.90%

Debt

Sales & Book Value

Annual Sales
$572.16 million
Cash Flow
$0.13 per share
Book Value
$2.52 per share

Miscellaneous

Free Float
N/A
Market Cap
$4.56 billion
Optionable
Not Optionable
Beta
0.98

Key Executives

  • Werner Lanthaler
    Chief Executive Officer
  • Craig L. Johnstone
    Chief Operating Officer & Member-Management Board
  • Enno Spillner
    Chief Financial Officer
  • Cord E. Dohrmann
    Chief Scientific Officer
  • Volker Braun
    SVP, Head-Investor Relations & ESG













EVTCY Stock - Frequently Asked Questions

Should I buy or sell Evotec stock right now?

0 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Evotec in the last year. There are currently for the stock. The consensus among Wall Street equities research analysts is that investors should "n/a" EVTCY shares.
View EVTCY analyst ratings
or view top-rated stocks.

How have EVTCY shares performed in 2022?

Evotec's stock was trading at $23.75 on January 1st, 2022. Since then, EVTCY stock has decreased by 41.9% and is now trading at $13.80.
View the best growth stocks for 2022 here
.

When did Evotec's stock split?

Evotec's stock split on the morning of Wednesday, October 20th 2021. The 3-1 split was announced on Wednesday, October 20th 2021. The newly minted shares were issued to shareholders after the closing bell on Wednesday, October 20th 2021. An investor that had 100 shares of stock prior to the split would have 300 shares after the split.

What is Evotec's stock symbol?

Evotec trades on the OTCMKTS under the ticker symbol "EVTCY."

How do I buy shares of Evotec?

Shares of EVTCY stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Evotec's stock price today?

One share of EVTCY stock can currently be purchased for approximately $13.80.

How much money does Evotec make?

Evotec (OTCMKTS:EVTCY) has a market capitalization of $4.56 billion and generates $572.16 million in revenue each year.

How many employees does Evotec have?

The company employs 3,572 workers across the globe.

How can I contact Evotec?

Evotec's mailing address is Manfred Eigen Campus Essener Bogen 7, Hamburg 2M, 22419. The official website for the company is www.evotec.com. The company can be reached via phone at (494) 056-0810, via email at investorrelations@evotec.com, or via fax at 49-40-5608-1222.

This page (OTCMKTS:EVTCY) was last updated on 8/17/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | contact@marketbeat.com | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Privacy Policy | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see Barchart's disclaimer.